Cormorant Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Cormorant Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25,000	Closed	-$2.16M	–	83
2020 Q1	$2.16M	Sell	25,000 -14,300	-36%	-$1.4M	0.1%	68
2019 Q4	$4.22M	Hold	39,300	–	–	0.17%	64
2019 Q3	$3.54M	Sell	39,300 -10,700	-21%	-$1,000K	0.22%	61
2019 Q2	$4.22M	Sell	50,000 -40,000	-44%	-$3.28M	0.24%	62
2019 Q1	$7.93M	Sell	90,000 -128,222	-59%	-$10.7M	0.54%	46
2018 Q4	$15.6M	Buy	218,222 +43,222	+25%	+$4.14M	1.27%	32
2018 Q3	$21.5M	Sell	175,000 -16,112	-8%	-$1.83M	1.4%	27
2018 Q2	$18.8M	Hold	191,112	–	–	1.39%	26
2018 Q1	$15.8M	Sell	191,112 -8,888	-4%	-$751K	1.18%	21
2017 Q4	$15.5M	Sell	200,000 -50,000	-20%	-$3.41M	1.62%	20
2017 Q3	$15.3M	Hold	250,000	–	–	2.71%	13
2017 Q2	$11.5M	Sell	250,000 -50,000	-17%	-$2.43M	1.91%	19
2017 Q1	$13M	Sell	300,000 -59,000	-16%	-$2.53M	1.89%	21
2016 Q4	$13.9M	Sell	359,000 -39,301	-10%	-$1.78M	1.87%	18
2016 Q3	$20.2M	Hold	398,301	–	–	2.22%	16
2016 Q2	$18.1M	Sell	398,301 -205,599	-34%	-$9.47M	2.57%	13
2016 Q1	$23.9M	Hold	603,900	–	–	3.6%	8
2015 Q4	$34.2M	Sell	603,900 -115,000	-16%	-$5.84M	4.09%	5
2015 Q3	$28.6M	Hold	718,900	–	–	4.57%	3
2015 Q2	$34.3M	Hold	718,900	–	–	4.56%	6
2015 Q1	$28.5M	Sell	718,900 -281,100	-28%	-$10.1M	4.41%	6
2014 Q4	$22.3M	Buy	1,000,000 +150,000	+18%	+$2.84M	3.44%	6
2014 Q3	$13.3M	Buy	850,000 +550,000	+183%	+$8.22M	2.74%	7
2014 Q2	$4.45M	Buy	+300,000	New	+$4.23M	1.18%	34

Other funds holding NBIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cormorant Asset Management's NBIX Position: Q2 2020 in Review

Cormorant Asset Management sold out of Neurocrine Biosciences (NBIX) in Q2 2020, closing a stake of 25,000 shares — an estimated $2.16M sold.

Cormorant Asset Management first reported a position in NBIX in Q2 2014 and held it in 24 quarters. The position peaked at $34.3M in Q2 2015. 418 funds tracked by Wall St. Rank hold NBIX as of Q2 2020.

Cormorant Asset Management reported no remaining Neurocrine Biosciences position as of Q2 2020 after selling out during the quarter.
Cormorant Asset Management sold 25,000 Neurocrine Biosciences shares in Q2 2020, an estimated $2.16M.
Cormorant Asset Management first reported a position in Neurocrine Biosciences in Q2 2014 and held it in 24 quarters.
Cormorant Asset Management's Neurocrine Biosciences position peaked at $34.3M in Q2 2015.
418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2020.

Based on Cormorant Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.